Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Endo pain drug meets end point in Phase III trial
The data from the analysis of 61 patients demonstrated that Rapinyl met its primary endpoint, the sum of pain intensity difference from baseline to 30 minutes (SPID 0-30),
The data from the analysis of 61 patients demonstrated that Rapinyl met its primary endpoint, the sum of pain intensity difference from baseline to 30 minutes (SPID 0-30),
Each unit consists of one common share and one-half of one common share purchase warrant. Each whole warrant entitles its holder to acquire one additional common share for
The completion of the transaction creates the largest single provider of workplace-based health, wellness and fitness services with more than 150 clients and more than 300 total site
Symmetry and DePuy will enter into a supply agreement which will require DePuy to make minimum purchases from the New Bedford facility for a four year period following
Baxter and Pfizer signed marketing, supply and manufacturing agreement for Gelfoam plus hemostasis kit. Under the terms of the agreement, Baxter is the exclusive distributor of Gelfoam plus
The oxycodone, administered as a single transdermal application, was safe with no adverse events reported. Oxycodone was detected in the subjects for at least 48 hours. The results
Bard’s Davol subsidiary, located in Cranston, Rhode Island, will begin marketing the line immediately. The Sepramesh IP product incorporates a polypropylene mesh with a layer of Sepra material
Under the collaboration, Oxford Genome Sciences (OGeS) and Amgen will generate fully human antibodies using Amgen’s XenoMouse technology, which was acquired through its acquisition of Abgenix. These antibodies
Under the terms of the agreement, the two commercial partners DNage and Solvay Pharmaceuticals will collaborate with eight top class academic groups to embark on a four year
The observed safety profile was consistent with earlier findings in clinical studies that led to the approval of bosentan (Tracleer 125mg bid) in pulmonary arterial hypertension (PAH). The